• Product name

    anti-Bevacizumab ELISA Kit (Avastin®)
    See all Bevacizumab kits
  • Detection method

  • Precision

    Sample n Mean SD CV%
    Overall < 15%
    Sample n Mean SD CV%
    Overall < 15%
  • Sample type

    Serum, Plasma
  • Assay type

    Sandwich (quantitative)
  • Sensitivity

    30 ng/ml
  • Range

    62 ng/ml - 500 ng/ml
  • Recovery

    Sample specific recovery
    Sample type Average % Range
    Serum 85% - 115%

  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    anti-Bevacizumab ELISA Kit (Avastin®) (ab237658) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Bevacizumab in biological matrices such as human serum and plasma.

    Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. It has been demonstrated that bevacizumab, in combination with chemotherapy, resulted in increased survival in patients with previously untreated metastatic colorectal cancer relative to chemotherapy alone, leading to FDA approval of the first antiangiogenic agent. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform



  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 96 tests
    Micro ELISA Plate 1 unit
    Bevacizumab standard 1 1 x 1ml
    Bevacizumab standard 2 1 x 1ml
    Bevacizumab Standard 3 1 x 1ml
    Bevacizumab Standard 4 1 x 1ml
    Bevacizumab Standard 5 1 x 1ml
    Bevacizumab Standard 6 1 x 1ml
    Bevacizumab Standard 7 1 x 1ml
    Assay Buffer 1 x 50ml
    Confirmation Reagent 1 x 12ml
    Peroxidase Conjugate 1 x 12ml
    TMB substrate 1 x 12ml
    Stop Solution 1 x 12ml
    Wash buffer (20X) 1 x 50ml
    Plate sealers 2 tablets
  • Relevance

    Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.


Our Abpromise guarantee covers the use of ab237658 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.


  • Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.



ab237658 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab237658.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up